炔诺酮

炔诺酮
临床资料
商品名（英语：Drug nomenclature）	Alone: Aygestin, Camila, Heather, Micronor, Primolut N, others; With EE: Lo Loestrin, Loestrin, Microgestin, Modicon, Norinyl, Ortho-Novum, others; With E2: Activella, Activelle, Estalis, Kliogest, Necon, Novofem, Trisequens, others
其他名称	NET; Norethindrone; NSC-9564; LG-202; Ethinylnortestosterone; Norpregneninolone; Anhydrohydroxy-norprogesterone; Ethinylestrenolone; 17α-Ethynyl-19-nortestosterone; 17α-Ethynylestra-4-en-17β-ol-3-one; 17α-Hydroxy-19-norpregn-4-en-20-yn-3-one
AHFS/Drugs.com	国际药品名称
MedlinePlus	a604034
给药途径	By mouth, intramuscular injection (as NETE)
药物类别（英语：Drug class）	Progestin; Progestogen
ATC码	G03AC01 (WHO) G03DC02;
药物动力学数据
生物利用度	47–73% (mean 64%)
血浆蛋白结合率	97%:; Albumin: 61%;; SHBG: 36%
药物代谢	Mainly CYP3A4 (liver); also 5α-/5β-reductase, 3α-/3β-HSD, and aromatase
生物半衰期	5.2–12.8 hours (mean 8.0 hours)
识别信息
	IUPAC命名法 (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; ;
CAS号	68-22-4
PubChem CID	6230;
IUPHAR/BPS	2880;
DrugBank	DB00717 ;
ChemSpider	5994 ;
UNII	T18F433X4S;
KEGG	D00182 ;
ChEBI	CHEBI:7627 ;
ChEMBL	ChEMBL1162 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID9023380 ;
ECHA InfoCard	100.000.619
化学信息
化学式	C20H26O2
摩尔质量	298.419 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像;
熔点	203至204 °C（397至399 °F）
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34;
	InChI InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1 ; Key:VIKNJXKGJWUCNN-XGXHKTLJSA-N ;

炔诺酮（英语：Norethisterone 或英语：norethindrone）是一种黄体制剂药物，用做口服避孕药和激素替代疗法药物以及治疗一些妇科疾病^[4]。

另见

醋酸炔诺酮，炔诺酮的乙酸酯

参考文献

^ ^1.0 ^1.1 Stanczyk, Frank Z. Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception (PDF). Reviews in Endocrine and Metabolic Disorders. Sep 2002, 3 (3): 211–224. ISSN 1389-9155. PMID 12215716. doi:10.1023/A:1020072325818.
^ Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.
^ Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. Mol. Biol. 2008, 110 (1–2): 56–66. PMID 18356043. doi:10.1016/j.jsbmb.2007.09.025.
^ Kathryn Rhodes Alden; Deitra Leonard Lowdermilk; Mary Catherine Cashion; Shannon E. Perry. Maternity and Women's Health Care - E-Book. Elsevier Health Sciences. 27 December 2013: 135– [2019-06-30]. ISBN 978-0-323-29368-6. （原始内容存档于2020-01-04）.

[pmid12215716-1] 1.0 ^1.1 Stanczyk, Frank Z. Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception (PDF). Reviews in Endocrine and Metabolic Disorders. Sep 2002, 3 (3): 211–224. ISSN 1389-9155. PMID 12215716. doi:10.1023/A:1020072325818.

[pmid8842581-2] Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.

[pmid18356043-3] Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. Mol. Biol. 2008, 110 (1–2): 56–66. PMID 18356043. doi:10.1016/j.jsbmb.2007.09.025.

[AldenLowdermilk2013-4] Kathryn Rhodes Alden; Deitra Leonard Lowdermilk; Mary Catherine Cashion; Shannon E. Perry. Maternity and Women's Health Care - E-Book. Elsevier Health Sciences. 27 December 2013: 135– [2019-06-30]. ISBN 978-0-323-29368-6. （原始内容存档于2020-01-04）.

[4]

[1]

[2]

[3]